CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
radiotherapyradiation
Likely dose
Prostate: 70 Gy; pelvic lymph nodes: 56 Gy via intensity-modulated radiation therapyAI-extracted
Key inclusion· 3
  • ✓Prostate cancer stage T1-T3
  • ✓Predicted risk of lymph node involvement >15%
  • ✓Gleason score >7
Key exclusion· 2
  • ✕Distant metastases present
  • ✕Currently on anticoagulant therapy

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00214136
NCT00214136Phase 2Completed
CompareCT.gov

A Phase II Prostate Cancer Trial Treating Pelvic Lymph Nodes to High Dose Using Intensity Modulated Radiation Therapy

University of Wisconsin, Madison·interventional·Posted Sep 21, 2005·Updated Aug 4, 2021

In Brief

A Phase 2 clinical trial evaluating radiotherapy for Prostate Cancer. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of this study is to examine the clinical feasibility and efficacy of uing IMRT to escalate the biologically effective dose to the pelvic lymph nodes in a short course of radiation therapy. An increased total and biologically effective dose will be delivered to the pelvic lymph nodes (56 Gy at 2 Gy/fraction). The prostate will receive standard "short course" IMRT of radiation (70 Gy at 2.5 Gy/fraction).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 21, 2005
Enrollment StartMar 1, 2005
Primary CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 11 yearsPosted 20.8 years ago

Interventions

radiotherapyradiation

prostate radiation to 70Gy; nodal radiation to 56Gy